The initial public offering (IPO) of Biopol Chemicals, a manufacturer of speciality chemicals, will open for public subscription on Friday, February 6, 2026. Through its maiden share sale, the company aims to raise ₹31.26 crore, entirely through a fresh issue of 2.9 million equity shares.
The issue will be listed on the NSE SME platform, making it one of the notable SME IPOs scheduled for February 2026.
Price band: ₹102 to ₹108 per share
Lot size: 1,200 equity shares
At the upper price band of ₹108, a retail investor bidding for two lots (2,400 shares) will need to invest ₹2,59,200.
Biopol Chemicals operates in the trading, manufacturing and distribution of speciality chemicals, serving multiple industrial segments through a business-to-business (B2B) model.
The company offers 66 products across four key categories:
40 silicone-based products
5 emulsifier-based products
15 biochemical products
6 polyelectrolyte products
Biopol caters to a wide range of sectors, including:
Textiles
Home care
Agriculture
Industrial chemicals
Biopol Chemicals operates through four establishments located in Gujarat and West Bengal, which include:
Manufacturing unit
Corporate office and warehouse in West Bengal
Registered office in Gujarat
This geographic presence supports its production, logistics and distribution requirements.
IPO opens: Friday, February 6, 2026
IPO closes: Tuesday, February 10, 2026
Basis of allotment: Wednesday, February 11, 2026
Shares credited to demat: Thursday, February 12, 2026
Listing on NSE SME: Friday, February 13, 2026
Registrar: Bigshare Services
Book-running lead manager: Smart Horizon Capital Advisors
As per the red herring prospectus (RHP), the company plans to utilise the net fresh issue proceeds as follows:
₹12.26 crore for the acquisition of industrial land
₹11.10 crore for repayment or prepayment of certain borrowings
Remaining funds for general corporate purposes
FY25 revenue from operations: ₹49.12 crore
FY24 revenue: ₹25.46 crore
This marks a near-doubling of revenue year-on-year.
FY25 EBITDA: ₹6.53 crore
FY24 EBITDA: ₹4.42 crore
EBITDA growth: 47.5%
FY25 PAT: ₹4.33 crore
FY24 PAT: ₹2.96 crore
The steady improvement in revenue and profitability highlights the company’s operational growth ahead of its public listing.
With exposure to the speciality chemicals segment, a diversified product portfolio, and improving financial metrics, the Biopol Chemicals IPO will be closely tracked by SME investors. However, as with all SME IPOs, investors should also consider liquidity, business scalability, and sector-specific risks before subscribing.
Disclaimer:
The information provided in this article on ThinkWithNiche is for informational and educational purposes only and should not be construed as investment advice, financial advice, or a recommendation to buy, sell, or hold any securities. All data, figures, and details are based on publicly available information and company disclosures at the time of writing and are believed to be accurate; however, ThinkWithNiche does not guarantee the completeness, accuracy, or reliability of the information.
Investing in initial public offerings (IPOs), especially SME IPOs, involves market risks, including the risk of loss of capital. Readers are advised to conduct their own research and due diligence and consult with a qualified financial advisor or registered investment professional before making any investment decisions. ThinkWithNiche, its authors, and affiliates shall not be held responsible for any financial losses or decisions taken based on the information presented in this article.